Skip to main
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is in a strong position thanks to its efficient operations, diversified revenue streams, and a well-established presence in the growing biotechnology, pharmaceutical, and medical device sectors. With a strong backlog and a robust pipeline, the company is well-positioned for future growth. Risks to consider include potential government funding delays and the possibility of not delivering clinical trials on time, but overall the company's fundamentals are solid and could support continued bookin

Bears say

Medpace Holdings is a full-service contract research organization with a high reliance on biopharma funding, presenting risks if funding dries up. Government shutdowns and volatility could also impact Medpace's ability to generate revenue. Additionally, the company's reliance on a few large metabolic programs presents a revenue risk in 2027 once those programs roll off. Despite improving bookings and commercial KPIs, Medpace may face margin pressure and uncertainty about competitive dynamics in the CRO space, causing downside risks to its shares.

Medpace Holdings (MEDP) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 9 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $570.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $570.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.